Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 182 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes European Parliament (EP) Draft Report on Psychosocial Risks at Work (PSR) as a Critical Opportunity to Protect the Wellbeing of the Cancer... FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma 2026 ESMO Breast Cancer Award Recipient Announced MOST POPULAR Company Gives Cancer Patient a New HVAC System After Treatment and... March 8, 2019 After Misdiagnosis, Mom Found Out She Had Terminal Breast Cancer Shortly... April 3, 2019 38% of Recurrent Breast Cancers Have a Different HER2 Status than... May 25, 2021 Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients... May 26, 2023 Load more HOT NEWS Time to get stratified Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness... Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin-Gemcitabine for the Treatment of Patients... Man Gets His First Haircut In 15 Years To Join The...
